Literature DB >> 7495842

The antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984) inhibits NADH oxidase activity of HeLa plasma membranes.

D J Morré1, L Y Wu, D M Morré.   

Abstract

Plasma membrane vesicles from HeLa S cells grown in culture bound with high affinity the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984). Based on binding site protection experiments with the radiolabeled thiol reagent N-[14C]ethylmaleimide, a ca. 34 kDa binding protein was identified. By analogy with a 36 kDa NADH oxidase from plant plasma membranes where activity was blocked by a growth-inhibitory herbicidal sulfonylurea, the sulfonylurea-binding protein of the HeLa plasma membranes has now been identified as a comparable sulfonylurea-inhibited NADH oxidase activity. The drug inhibited half maximally at about 50 nM which corresponded closely to the Kd for binding of [3H]LY181984 of 25 nM. A closely related but growth-inactive sulfonylurea N-(4-methylphenylsulfonyl)-N'-(phenyl)urea (LY181985) inhibited the activity only weakly. The inhibition by LY181984 was analyzed kinetically and shown to be noncompetitive or uncompetitive depending on the concentration of NADH. With sealed right-side out plasma membrane vesicles, the NADH oxidase activity was about 90% inhibited by 1 microM LY181984. With frozen and thawed plasma membrane vesicles or with vesicles first solubilized with 1% Triton X-100, activity also was inhibited by LY181984 and not by LY181985 but the maximum inhibition at 10 microM LY181984 was about 50%. With plasma membranes from rat liver, neither LY181984 nor LY181985 affected the NADH oxidase even in the presence of detergent. Thus, selective inhibition or stimulation of the oxidation of NADH of tumor plasma membranes by the antitumor sulfonylurea LY181984 may be related to its antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495842     DOI: 10.1016/0005-2736(95)00164-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Structural changes revealed by Fourier transform infrared and circular dichroism spectroscopic analyses underlie tNOX periodic oscillations.

Authors:  Chinpal Kim; Sara Layman; Dorothy M Morré; D James Morré
Journal:  Dose Response       Date:  2006-05-01       Impact factor: 2.658

2.  Decomposition Analyses Applied to a Complex Ultradian Biorhythm: The Oscillating NADH Oxidase Activity of Plasma Membranes Having a Potential Time-Keeping (Clock) Function.

Authors:  Ken Foster; Nasim Anwar; Rhea Pogue; Dorothy M Morré; T W Keenan; D James Morré
Journal:  Nonlinearity Biol Toxicol Med       Date:  2003-01

3.  The sulfonylurea-inhibited NADH oxidase activity of HeLa cell plasma membranes has properties of a protein disulfide-thiol oxidoreductase with protein disulfide-thiol interchange activity.

Authors:  D J Morré; P J Chueh; J Lawler; D M Morré
Journal:  J Bioenerg Biomembr       Date:  1998-10       Impact factor: 2.945

4.  A circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea N-4-(methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984) specific to sera from cancer patients.

Authors:  D J Morré; T Reust
Journal:  J Bioenerg Biomembr       Date:  1997-06       Impact factor: 2.945

5.  Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin?

Authors:  D J Morré; C Kim; M Paulik; D M Morré; W P Faulk
Journal:  J Bioenerg Biomembr       Date:  1997-06       Impact factor: 2.945

6.  Phenoxodiol treatment alters the subsequent response of ENOX2 (tNOX) and growth of hela cells to paclitaxel and cisplatin.

Authors:  D James Morré; Nicole McClain; L-Y Wu; Graham Kelly; Dorothy M Morré
Journal:  Mol Biotechnol       Date:  2009-01-21       Impact factor: 2.695

7.  Benzo[b]thiophenesulphonamide 1,1-dioxide derivatives inhibit tNOX activity in a redox state-dependent manner.

Authors:  I Encío; D J Morré; R Villar; M J Gil; V Martínez-Merino
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

8.  ENOX2 target for the anticancer isoflavone ME-143.

Authors:  D James Morré; Theodore Korty; Christiaan Meadows; Laura M C Ades; Dorothy M Morré
Journal:  Oncol Res       Date:  2014       Impact factor: 5.574

9.  Bis(chloroacetamidino)-Derived Heteroarene-Fused Anthraquinones Bind to and Cause Proteasomal Degradation of tNOX, Leading to c-Flip Downregulation and Apoptosis in Oral Cancer Cells.

Authors:  Jeng Shiun Chang; Chien-Yu Chen; Alexander S Tikhomirov; Atikul Islam; Ru-Hao Liang; Chia-Wei Weng; Wei-Hou Wu; Andrey E Shchekotikhin; Pin Ju Chueh
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.